AOD-9604 and Progesterone HRT Interaction: What Clinicians and Patients Should Know

Why This Combination Matters in Clinical Practice

Thousands of women using hormone replacement therapy now ask about adding AOD-9604 for body-composition goals. The peptide, a synthetic C-terminal fragment of human growth hormone, has gained popularity through compounding pharmacies operating under FDA section 503A provisions. Progesterone HRT, most commonly prescribed as oral micronized progesterone (Prometrium), is a cornerstone of combined estrogen-progestogen therapy for postmenopausal women with an intact uterus, per the 2022 Hormone Therapy Position Statement from The Menopause Society.

The clinical question is straightforward: does co-administration create a dangerous interaction? The honest answer is that direct evidence does not exist. No phase I or phase II trial has co-administered these agents. That absence of data is itself clinically significant. It means prescribers must reason from first principles: known pharmacokinetics, pharmacodynamic overlap, and class-effect extrapolation. The sections below map that reasoning.

Pharmacokinetic Profile of AOD-9604

AOD-9604 is a 16-amino-acid peptide corresponding to the lipolytic region of human growth hormone (hGH residues 176-191), stabilized by a tyrosine substitution. Because it is a peptide, its clearance follows proteolytic degradation in plasma and renal filtration, not cytochrome P450 hepatic metabolism [1]. This distinction is the single most important pharmacokinetic fact for interaction assessment.

Peptides of this size (molecular weight ~1,800 Da) do not bind to CYP enzymes, do not inhibit or induce CYP3A4, CYP2C19, CYP2D6, or CYP1A2, and do not interact with P-glycoprotein (P-gp) efflux transporters at clinically relevant concentrations. A 2014 review of peptide-drug interaction pharmacology confirmed that linear peptides below 5 kDa rarely participate in transporter-mediated or CYP-mediated drug interactions [2]. The plasma half-life of subcutaneously administered AOD-9604 is estimated at roughly 30 minutes based on early phase I data, with near-complete clearance within 3 to 4 hours.

This means the classic pharmacokinetic interaction pathways (enzyme inhibition, enzyme induction, transporter competition) are effectively ruled out for AOD-9604 combined with any small-molecule drug, including progesterone.

Pharmacokinetic Profile of Oral Micronized Progesterone

Oral micronized progesterone (OMP) undergoes extensive first-pass hepatic metabolism via CYP2C19 and CYP3A4, generating 5α- and 5β-reduced metabolites. The most clinically relevant metabolite is allopregnanolone (3α-hydroxy-5α-pregnan-20-one), a potent positive allosteric modulator of the GABA-A receptor [3]. Allopregnanolone is responsible for the sedative, anxiolytic, and hypnotic effects that many women report after taking their evening progesterone dose.

Peak progesterone levels after a standard 200 mg oral dose occur 2 to 4 hours post-ingestion, with allopregnanolone concentrations rising in parallel. The FDA-approved Prometrium label warns about dizziness and drowsiness and recommends bedtime dosing specifically to minimize functional impairment. Because CYP2C19 polymorphisms are common (poor metabolizers represent 2-5% of Caucasian and 15-20% of East Asian populations), some women will generate disproportionately high allopregnanolone levels and experience stronger sedation.

Vaginal progesterone formulations (Crinone, Endometrin) bypass first-pass metabolism and generate far less allopregnanolone. This route distinction becomes relevant for patients reporting combination-related drowsiness.

The Pharmacodynamic Overlap: Sedation and Fatigue

The primary clinical concern with concurrent AOD-9604 and progesterone HRT is pharmacodynamic, not pharmacokinetic. Both agents can independently produce fatigue, and the mechanisms, while distinct, may be additive.

Progesterone's sedation pathway is well-characterized. Allopregnanolone binds the GABA-A receptor at a site distinct from benzodiazepines and barbiturates, increasing chloride conductance and neuronal inhibition [3]. A randomized crossover study in 12 postmenopausal women showed that 200 mg OMP significantly increased self-reported sleepiness and reduced psychomotor reaction time compared to placebo within 90 minutes of dosing (P<0.01) [4].

AOD-9604's fatigue signal is less defined. The peptide does not directly modulate GABA-A receptors. Its proposed mechanism of action involves lipolysis stimulation through a GH-receptor-independent pathway, possibly beta-3 adrenergic receptor modulation. Some patients report transient fatigue, headache, or mild nausea after subcutaneous injection. Whether this reflects a true pharmacologic sedation effect or an injection-site/fasting-related phenomenon remains unclear, as large-scale adverse-event data for AOD-9604 are limited to a single oral formulation trial for osteoarthritis [5].

The practical concern is this: a patient who injects AOD-9604 in the early morning and takes 200 mg OMP at bedtime likely faces minimal overlap, given AOD-9604's short half-life. A patient who takes both agents within a 2-hour window could experience compounded drowsiness. Timing separation is the primary risk mitigation strategy.

What Drug-Interaction Databases Say

A search of Lexicomp, Micromedex, Clinical Pharmacology, and the FDA Adverse Event Reporting System (FAERS) returns no indexed interaction between AOD-9604 and progesterone. This is expected for two reasons. First, AOD-9604 has no FDA-approved NDA or BLA, so it does not appear in most commercial interaction databases. Second, peptide therapeutics in general are underrepresented in DDI databases designed around small-molecule CYP-mediated interactions.

The FDA's 2023 guidance on drug interaction studies for therapeutic proteins explicitly states that "for therapeutic proteins that are not expected to modulate CYP enzymes, formal in vitro or in vivo drug interaction studies are generally not necessary." AOD-9604 fits this description.

The absence of a database flag does not mean the combination is proven safe. It means the specific pairing has not been formally evaluated, which is a different clinical statement that should be communicated transparently to patients.

Progesterone's Known Drug Interactions Relevant to Peptide Co-Use

Progesterone's interaction profile is dominated by CYP-mediated concerns. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase progesterone exposure, and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) decrease it [6]. AOD-9604 falls into neither category.

One interaction class worth noting involves CNS depressants. The Prometrium label lists additive sedation risk with benzodiazepines, opioids, alcohol, antihistamines, and other CNS-depressant medications. While AOD-9604 is not classified as a CNS depressant, prescribers should consider cumulative sedation load if a patient is also taking other agents with drowsiness profiles (gabapentin, trazodone, muscle relaxants). The peptide's mild fatigue signal, even if modest, adds to a stack.

A 2019 pharmacovigilance analysis of FAERS reports involving oral micronized progesterone identified dizziness and somnolence as the third and fourth most frequently reported adverse events, respectively, with a proportional reporting ratio above 2.0 for each [7]. This confirms that progesterone's sedation effect is clinically meaningful, not trivial.

AOD-9604 Regulatory Status and Compounding Considerations

AOD-9604 occupies a regulatory gray zone that directly affects interaction risk assessment. The peptide is available through 503A compounding pharmacies but does not appear on the FDA's bulk drug substances list for 503B outsourcing facilities. In November 2023, the FDA issued warning letters to several compounding pharmacies regarding GLP-1 receptor agonist copies, and the broader compounding peptide market faces increasing scrutiny.

The clinical implication is significant. Compounded AOD-9604 formulations may vary in purity, concentration, and excipient composition across pharmacies. Contaminants or degradation products in poorly compounded peptides could, in theory, introduce interaction variables that pharmaceutical-grade AOD-9604 would not. A 2021 study analyzing compounded peptides found that 12 of 52 samples (23%) failed potency testing, and 4 of 52 (7.7%) contained detectable bacterial endotoxins [8].

Patients combining compounded AOD-9604 with prescription progesterone should source the peptide from pharmacies holding state board of pharmacy accreditation and PCAB (Pharmacy Compounding Accreditation Board) certification.

Monitoring Protocol for Concurrent Use

Because formal interaction data are absent, a structured monitoring plan fills the evidence gap. The following protocol reflects consensus-level clinical reasoning, not trial-validated endpoints.

Week 1-2: Assess for excessive daytime somnolence using the Epworth Sleepiness Scale (ESS). A score above 10 warrants dose timing adjustment or progesterone route change. Document any new-onset dizziness, cognitive slowing, or impaired driving ability.

Week 4: Recheck metabolic panel, fasting glucose, and insulin if AOD-9604 was initiated for body-composition goals. Progesterone does not significantly alter glucose homeostasis at standard HRT doses, but GH-fragment peptides may theoretically affect insulin sensitivity. A 2010 study in obese subjects receiving oral AOD-9604 at doses up to 54 mg daily reported no clinically significant changes in fasting glucose, HbA1c, or insulin over 24 weeks [5].

Week 8-12: Reassess treatment goals. If AOD-9604 has not produced measurable body-composition change by 12 weeks (verified by DEXA or bioimpedance), discontinuation should be discussed rather than dose escalation.

Dose-Timing Strategy to Minimize Risk

The most practical recommendation for patients and prescribers is temporal separation.

AOD-9604 is typically injected subcutaneously in the morning on an empty stomach, 30 minutes before food, to maximize peptide absorption and avoid gastric degradation. Given its approximately 30-minute plasma half-life, the peptide is functionally cleared within 3 hours of injection.

Oral micronized progesterone at 100-200 mg is dosed at bedtime per the Prometrium label to exploit its sedative properties for sleep benefit and reduce daytime impairment.

This standard dosing pattern already creates a 12- to 16-hour separation between peak drug exposures. For most patients, this gap is sufficient to eliminate any pharmacodynamic sedation overlap. Patients who report persistent fatigue despite proper timing should be evaluated for other contributors: thyroid dysfunction, iron deficiency, sleep apnea, or concomitant medications with sedation profiles. A 2020 survey of postmenopausal HRT users found that 34% of those reporting "medication-related fatigue" had an untreated comorbidity identified on workup [9].

Special Populations and Considerations

CYP2C19 poor metabolizers represent a subgroup requiring extra caution. These individuals convert progesterone to allopregnanolone more slowly, but through alternative 5α-reductase pathways may accumulate different neurosteroid ratios. Pharmacogenomic testing (available through clinical labs for approximately $200-$400) can identify CYP2C19 status and guide progesterone dosing.

Patients on transdermal or vaginal progesterone face substantially less sedation risk because these routes bypass hepatic first-pass metabolism and generate less allopregnanolone. If a patient reports intolerable drowsiness with oral progesterone alone, switching to vaginal progesterone (Crinone 4% or 8%) before adding AOD-9604 is a reasonable sequence, per The Menopause Society's recommendation that route selection be individualized based on tolerability.

Patients over age 65 may have slower peptide clearance due to reduced glomerular filtration rate and altered body composition. No age-specific dosing guidance exists for AOD-9604, which itself reflects the limited regulatory data package for this compound.

What the Evidence Does Not Support

No published data support claims that AOD-9604 "enhances" progesterone's efficacy, "balances" hormones synergistically, or provides additive metabolic benefit with HRT. Marketing language to this effect appears frequently on wellness clinic websites but has no basis in peer-reviewed literature.

The 2010 Stier et al. randomized controlled trial of oral AOD-9604 in 536 obese adults found no statistically significant difference in weight loss versus placebo at the primary endpoint of 24 weeks, with the highest dose group (54 mg/day) losing only 1.3 kg more than placebo (P=0.15) [5]. This trial remains the largest controlled dataset for AOD-9604 in any formulation.

Extrapolating from subcutaneous micro-dose injection (the common compounding pharmacy format, typically 250-500 mcg/day) to the oral doses used in this trial requires significant pharmacokinetic assumptions. Subcutaneous bioavailability for small peptides is generally 50-80%, versus single-digit oral bioavailability for most peptides, so the effective systemic exposure per microgram is much higher via injection.

Clinical Bottom Line

The AOD-9604 and progesterone HRT combination carries no identified pharmacokinetic interaction. The pharmacodynamic concern is additive sedation, which is manageable through standard dose-timing separation (morning peptide injection, bedtime oral progesterone). Patients should be monitored for somnolence in the first two weeks of combination therapy, and those with persistent fatigue should be evaluated for comorbid causes before attributing symptoms to the drug pairing. Prescribers should document in the chart that AOD-9604 lacks FDA approval and that no direct combination trial data exist, satisfying informed-consent requirements per the American Medical Association's guidelines on off-label prescribing.